Partner with Foresight to access
MRD assays that rise above the noise.

The Challenge

Existing MRD assays lack sensitivity when disease burden is low.

Existing liquid biopsy tests are unable to confidently differentiate between cancer patients who are cured and those who will experience progression when disease burden is low. Spontaneous and benign SNVs occur at high enough frequency to obscure the scant presence of tumor-associated SNVs. The inherent error rate of NGS-based testing further masks low-allelic frequency mutations. This background noise results in missed relapses hiding in plain sight.

Our Solution

PVphased variant (i.e. multiple SNVs) SNVsingle nucleotide variant vs mutational signal : noise ctDNA

Foresight CLARITY: the best-in-class approach to ctDNA monitoring.

Single nucleotide variations are common and counting them can be inconclusive due to the inherent error rates of NGS. But Foresight CLARITY is powered by phased variants (PVs), which are multiple SNVs found on a single sequencing read, can be uniquely attributed to malignant cells. PVs commonly occur in all types of cancers, and by specifically monitoring tumor-specific PVs, we have attained unmatched MRD sensitivity.

By leveraging this untapped biology in cancers, we’re able to identify MRD at levels below the detection limit of conventional NGS-based ctDNA assays. We cut the noise that leading error suppression methods like duplex sequencing and barcoding can’t.

Personalized analysis without
personalized panels.

Foresight CLARITY detects MRD across liquid and solid tumors with unprecedented sensitivity and specificity.

In lymphomas and other blood cancers, validated mutational signatures eliminate the need for customized assays, expediting MRD-guided research and treatment with personalized analysis, from off-the-shelf panels.

Unprecedented clarity
at every step of treatment.

dropletLymphoma & Blood Cancers

treatment step 1treatment step 1


Unlike personalized MRD assays that require exome sequencing and patient-specific panel design, Foresight CLARITY for Lymphoma is an off-the-shelf panel that can be used to measure extremely low amounts of ctDNA from plasma, giving up to 100X improved sensitivity of cancer detection that results in identifying recurrence an average of 200 days earlier1 than conventional methods.

treatment step 2 treatment step 2

Diagnosis /
Trial Enrollment

Assay pre-treatment plasma DNA for personalized PV genotyping via targeted sequencing.

No tumor sample needed.

treatment step 3 treatment step 3


Mid- and end-of-treatment plasma ctDNA used for MRD assessment.
Treatment plan is informed by ctDNA levels.


treatment step 4 treatment step 4


Post-treatment plasma DNA used for longitudinal cancer surveillance.

check mark

No tumor samples or customization needed

check mark

Assays performed at our CLIA-certified lab

More About Foresight CLARITY for Lymphoma

solid tumors Solid Tumors

Foresight CLARITY for Solid Tumors is personalized based on patient-specific phased variants that are identified with whole-genome sequencing. It offers the same degree of sensitivity as Foresight CLARITY for Lymphoma and has the ability to track oncogenic and clinically relevant SNVs in addition to other tumor-specific phased variants.

More About Foresight CLARITY for Solid Tumors

partnering options

CLIA assay

Smarter companion diagnostic development.

Use our Foresight CLARITY MRD platform to enrich patient populations for those with the highest likelihood of responding to a given therapy. Screen less patients and complete trial recruitment faster.

CLIA Assay
MRD-driven clinical trials

Within the same patient population, there are twice as many participants eligible to enroll your MRD-driven trial than you think. We capture the false negatives others missed.

MRD as an exploratory endpoint

Assess MRD over the course of a treatment regimen to quantify depth of response.

MRD as a surrogate endpoint

Accelerate trial completion by using MRD negativity as surrogate endpoint.

research assay

One assay.
Many applications.

Foresight CLARITY is also available outside of our CLIA lab as a ctDNA research assay, and can answer a wide variety of pressing questions in translational research. Quantify and monitor disease burden over time in both solid tumors and blood cancers.

Rsearch Assay

Comprehensive and customizable SNV and CNV genotyping unlocks biological insights, such as mechanisms of response and resistance.

Precision / personalized medicine

Identify actionable mutations and classify patients into genotypically-defined molecular subtypes, including cell of origin determination for DLBCL.

Relapse detection

Identify recurrent disease with up to 100x improved sensitivity compared to existing MRD assays.

Patient stratification

Separate responders from non-responders based on genotype, mutational status, or changes in disease burden.

Meet our team right arrow Submit application for research use right arrow

1 Kurtz, D.M., Soo, J., Co Ting Keh, L. et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol 39, 1537–1547 (2021)

2 Roschewski, M., Kurtz, D.M., Westin, J. et al. MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design. Blood (2022) 140 (Supplement 1): 785–786.

3 Isbell, J.M., Li, B.T., Eichholtz, J.E. et al. Ultrasensitive ctDNA MRD Monitoring in early stage lung cancer with PhasED-Seq. Poster, AACR 2023 Annual Meeting